#United States #Cardiac Care #Avertix Medical #Guardian System #EATONTOWN

Avertix Medical's Guardian System Confirmed as Cost-Effective for High-Risk Acute Coronary Syndrome Patients

Avertix Medical, Inc., a groundbreaking company in the cardiac care industry, has recently made headlines with the confirmation of the cost-effectiveness of its Guardian System. This revolutionary device is recognized as the world's first real-time, continuous heart monitoring and alerting system specifically designed for high-risk acute coronary syndrome (ACS) patients. The study showcasing the economic viability of this life-saving technology was conducted by top researchers from the esteemed Duke Clinical Research Institute, with findings published in the respected journal, Future Cardiology.

The Guardian System stands out as a significant advancement in the realm of cardiac care. Through a comprehensive analysis that utilized data from the pivotal ALERTS clinical trial along with other relevant research findings, it was determined that the system offers an incremental cost-effectiveness ratio (ICER) of $58,668 per quality adjusted life year (QALY). This finding aligns with conventional cost-effectiveness thresholds and presents a favorable comparison to other implantable cardiac technologies.

Tim Moran, President and Chief Executive Officer of Avertix Medical, expressed optimism regarding the implications of this study. He stated, "The findings from this study further validate The Guardian system as a proactive clinical option in addressing the critical unmet need for early detection and intervention in high-risk ACS patients. This economic profile adds an important datapoint to what our physician partners already know about clinical benefits—real-time, continuous intracardiac monitoring can be a game-changer for patients at risk of recurrent cardiac events."

The Guardian System enables patients and healthcare providers to detect early warning signs of cardiac events in real time, even in cases of silent ischemia. This capability is crucial for improving patient outcomes, as it facilitates earlier hospital arrival during emergencies, preventing further complications and enhancing quality of life.

Lead author Gillian Sanders Schmidler highlighted the importance of reducing delays in treatment for ACS patients. She emphasized, "Reducing delay between the onset of occlusion and guideline-directed medical management is a well-accepted treatment goal for high-risk ACS patients. Our analysis supports that the use of The Guardian system with these patients not only improves health outcomes but is economically attractive when compared to standard of care."

As the only FDA-approved implantable heart attack warning system that provides real-time alerts, the Guardian's relevance in contemporary healthcare systems cannot be understated. The study strengthens the case for broader adoption of this technology among healthcare providers, payers, and policymakers who are all focused on improving long-term patient outcomes and reducing emergency care costs.

For more information about the Guardian System and its transformative impact on cardiac care, potential patients and providers are encouraged to visit Avertix's website. Additionally, for those interested in delving deeper into the full economic analysis, a link is available here.

Overall, Avertix Medical is dedicated to pioneering innovative solutions that enhance early detection and intervention in cardiac care, and the Guardian System is a testament to their commitment to improving patient lives.